Academic Journal
Q1Neurology and Therapy
About Neurology and Therapy
Neurology and Therapy is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q1, with an SJR of 1.386 and H-index of 47.
Coverage: 2012-2026. Research categories: Neurology (Q1); Neurology (clinical) (Q1).
Verified field sources
- Journal Impact Factor: 4.7 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-03-17. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Multiple Sclerosis Research Studies; Peripheral Neuropathies and Disorders; Dementia and Cognitive Impairment Research; Alzheimer's disease research and treatments; Parkinson's Disease Mechanisms and Treatments; Epilepsy research and treatment.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Time Course of Rimegepant Effect for Acute Treatment of Migraine in Adults Unsuitable for Triptans: Exploratory Endpoints from a Phase 4, Randomized, Double-Blind, Placebo-Controlled Study
Michel Lanteri-Minet, Timothy Smith, Catherine Nalpas, Luz M. Ramirez et al.
2026-10-03 · DOI: 10.1007/s40120-026-01043-6Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025–2029): Updated Insights from the Oracle Model
Diego Centonze, Massimiliano Calabrese, Eleonora Cocco, Roberta Di Turi et al.
2026-10-03 · DOI: 10.1007/s40120-026-01042-7Perspectives of Adult Patients and Caregivers on the Management and Challenges Associated with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Multinational Qualitative Survey
Ayo Adeyemi, Susanna Burckhardt, Riccardo Buttarelli, Michelle Erdmann et al.
2026-09-30 · DOI: 10.1007/s40120-026-01018-7Impact of Oral Cladribine on TSPO-PET-Measurable Immune Cell Activation in Multiple Sclerosis
Olli Rajalehto, Markus Matilainen, Jussi Lehto, Eveliina Honkonen et al.
2026-09-30 · DOI: 10.1007/s40120-026-01044-5From Biomarker Anchors to Disease-State Transitions: A Biologically Anchored Probabilistic Principal Component Analysis Framework for Alzheimer’s Disease Progression Modeling
Babak Haji, Amir Abbas Tahami Monfared
2026-09-28 · DOI: 10.1007/s40120-026-01036-5Correction: Patient Experience with 10 mg Intranasally Administered Zavegepant as an Acute Treatment of Migraine Attacks: Qualitative Research Findings
Noah Rosen, Heather Moran, Josh Coulter, Alexandra Kissling et al.
2026-09-25 · DOI: 10.1007/s40120-026-01034-7Comparative Efficacy of Rozanolixizumab with Efgartigimod or Intravenous Immunoglobulin in Generalized Myasthenia Gravis Using Matching Adjusted Indirect Comparisons
Vikalp Maheshwari, Carolina Barnett Tapia, Abhiroop Chakravarty, Jitender Takyar et al.
2026-09-24 · DOI: 10.1007/s40120-026-01020-zMaintenance of Minimal Manifestation Status with Individualized-Interval Efgartigimod in Generalized Myasthenia Gravis: Study Protocol for a Single-Arm, Open-Label Clinical Trial
Tetsu Suzuki, Motoki Fujimaki, Kota Igari, Shogo Ohuchi et al.
2026-09-24 · DOI: 10.1007/s40120-026-01031-wComparative Efficacy of Zilucoplan Versus Intravenous Immunoglobulin, Eculizumab, and Ravulizumab Using Matching-Adjusted Indirect Comparisons
April Betts, Saiju Jacob, Abhiroop Chakravarty, Jitender Takyar et al.
2026-09-24 · DOI: 10.1007/s40120-026-01021-yThe Role of Neurologists in the Management of Uncontrolled Epilepsy in Spain: Opportunities for Optimization
David García-Azorín, Luis Lobato, Javier Riancho, Juan J. Poza et al.
2026-09-22 · DOI: 10.1007/s40120-026-01039-2Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Spain, Greece, and Portugal
Raquel Yahyaoui, Argirios Dinopoulos, Francina Munell, José Pedro Vieira et al.
2026-09-21 · DOI: 10.1007/s40120-026-01032-9Benzodiazepines in Epilepsy: A US Perspective on Clinical Use, Pharmacology, Abuse Methods, and Public Health Considerations
Enrique Carrazana, Joseph Sirven, John Stern, Barry Gidal et al.
2026-09-17 · DOI: 10.1007/s40120-026-01007-wTreatment Preferences of Physicians of Pediatric Patients with Attention-Deficit/Hyperactivity Disorder in the United States and Canada: A Discrete Choice Experiment
Jeff Schein, Marjolaine Gauthier-Loiselle, Yan Meng, Maryaline Catillon et al.
2026-09-15 · DOI: 10.1007/s40120-026-01033-8Evaluation of Autonomic and Cognitive Functions in Patients with Essential Tremor
Eda Özsezen, Nevin Pazarci
2026-09-15 · DOI: 10.1007/s40120-026-01035-6Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCE
Richard B. Lipton, Peter J. Goadsby, Patricia Pozo-Rosich, Alexandre Urani et al.
2026-09-09 · DOI: 10.1007/s40120-026-01024-9Update on Parkinson’s Disease Psychosis: Epidemiology, Mechanisms and Management
Caroline Kruse, Daniel Weintraub, John Duda, James F. Morley et al.
2026-09-09 · DOI: 10.1007/s40120-026-01014-xCenobamate Improves Emotional Dysregulation, Impulsivity, and Apathy in Drug-Resistant Focal Epilepsy: A Longitudinal Neuropsychological Study
Ilaria Sammarra, Adriana Saraceno, Iolanda Martino, Alessia Vono et al.
2026-09-08 · DOI: 10.1007/s40120-026-01022-xCharacteristics and Hospitalization Details of Patients with Advanced Parkinson’s Disease Receiving Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa: Real-World First-Year Descriptive Study from Japan
Toru Baba, Toshiki Nozaki, Shunji Toya, Hideyuki Migita et al.
2026-10 · DOI: 10.1007/s40120-026-01016-9Smartphone-Based Multimodal Digital Biomarker Integration for Parkinson’s Disease Screening and Diagnostic Support
Kyungsung Lee, Han-Joon Kim, Jung Hwan Shin, Seungmin Lee et al.
2026-10 · DOI: 10.1007/s40120-026-01023-wArtificial Intelligence in Neuromuscular Diseases: Opportunities for a Data-Scarce Field
Shang Ma, Sushan Luo, Huahua Zhong
2026-10 · DOI: 10.1007/s40120-026-01017-8Reviews
Community Reviews
Version History
September 25, 2026 at 7:31 am
September 25, 2026